Dr. Bauml on Next Steps for Immunotherapy in Head and Neck Cancer

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.

The next steps for immunotherapy in this disease is moving it earlier in the course of treatment, says Bauml.

For example, neoadjuvant pembrolizumab (Keytruda) showed major pathologic responses after a single dose in patients with resectable tumors.